Clinical results of long-term slow-release lanreotide treatment of acromegaly

被引:57
作者
Giusti, M
Ciccarelli, E
Dallabonzana, D
Delitala, G
Faglia, G
Liuzzi, A
Gussoni, G
Disem, GG
机构
[1] UNIV TURIN,DIPARTIMENTO FISIPATOL CLIN,TURIN,ITALY
[2] OSPED MAGGIORE NIGUARDA,DIV ENDOCRINOL,MILAN,ITALY
[3] UNIV SASSARI,IST EMATOL & ENDOCRINOL,I-07100 SASSARI,ITALY
[4] UNIV MILAN,IST SCI ENDOCRINE,MILAN,ITALY
[5] OSPED CASA SOLLIEVO SOFFERENZA,DIV ENDOCRINOL,SAN GIOVANNI ROTO,ITALY
[6] IPSEN SPA,MILAN,ITALY
关键词
acromegaly; effectiveness; GH/IGF-1; lanreotide SR; tolerability;
D O I
10.1046/j.1365-2362.1997.1190659.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Medical therapy is frequently needed to normalize growth hormone/insulin-like growth factor I secretion in acromegaly. The aim of this study was to determine the long-term effects of the slow-release (SR) somatostatin analogue lanreotide in 57 acromegalic patients. SR lanreotide (30mg) was given every 14 days for 12 months. In 33% of patients, the drug dosage was raised to 60 mg and/or the time interval was shortened to 10 days. Two months of clinical evaluation followed drug discontinuation in 47 out of 48 (84%) patients who completed the 12-month period. A drug-related decrease in GH/ IGF-I levels was observed. Basal GH/IGF-I levels were significantly (P < 0.001) reduced at 12 months. IGF-I was normalized in 35% of patients and GH levels were <5 mu gL(-1) in 54%. There was a clinical improvement in patients complaining of joint pain, rachialgias, headache, digital paraesthesias and hyperhidrosis. Soft-tissue changes were documented by significant (P < 0.001) decreases in finger size. In 52 (91%) patients without overt diabetes, a slight but significant increase in integrated glycaemia (P < 0.001) was noted, while integrated insulin levels were reduced (P< 0.001). Of 33 (58%) patients with normal basal ultrasound examination of the gall bladder, three (9%) had developed asymptomatic gall stones or biliary sludge after 12 months. Adverse events were generally mild. They frequently (52%) occurred after the first SR lanreotide administration; only 28% were recurrent and 20% appeared for the first time during therapy. SR lanreotide is an effective treatment in most unselected acromegalic patients. Tolerance towards the drug is high. Subjective benefits seem to override the simple biochemical control of the disease. Glucose homeostasis more than the incidence of gall stones seems to require monitoring on therapy. SR lanreotide is clearly advantageous in improving patient compliance with medical treatment for acromegaly.
引用
收藏
页码:277 / 284
页数:8
相关论文
共 37 条
[1]   EFFECTS OF TREATMENT WITH OCTREOTIDE IN ACROMEGALIC PATIENTS - A MULTICENTER ITALIAN STUDY [J].
AROSIO, M ;
MACCHELLI, S ;
ROSSI, CM ;
CASATI, G ;
BIELLA, O ;
FAGLIA, G ;
MARTINO, E ;
SQUATRITO, S ;
GIUSTI, M ;
CANNAVO, S ;
VELARDO, A ;
SICOLO, N ;
BARBARINO, A ;
TAMBURRANO, G ;
CICCARELLI, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 133 (04) :430-439
[2]   EFFECT OF OCTREOTIDE ON CIRCULATING IGF-I CHROMATOGRAPHIC PROFILE - EVIDENCE FOR AN INHIBITORY-ACTION ON THE FORMATION OF THE 150-KDA TERNARY COMPLEX [J].
BARRECA, A ;
CARIOLA, G ;
PONZANI, P ;
ARVIGO, M ;
FOPPIANI, L ;
GIORDANO, G ;
MINUTO, F .
CLINICAL ENDOCRINOLOGY, 1995, 42 (02) :161-167
[3]   INSULIN-LIKE GROWTH FACTOR-I AND DAILY GROWTH-HORMONE PROFILE IN THE ASSESSMENT OF ACTIVE ACROMEGALY [J].
BARRECA, A ;
CICCARELLI, E ;
MINUTO, F ;
BRUZZI, P ;
GIORDANO, G ;
CAMANNI, F .
ACTA ENDOCRINOLOGICA, 1989, 120 (05) :629-635
[4]   DOES TREATMENT OF ACROMEGALY AFFECT LIFE EXPECTANCY [J].
BATES, AS ;
VANTHOFF, W ;
JONES, JM ;
CLAYTON, RN .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (01) :1-5
[5]   INTRAMUSCULAR INJECTIONS OF SLOW-RELEASE LANREOTIDE (BIM-23014) IN ACROMEGALIC PATIENTS PREVIOUSLY TREATED WITH CONTINUOUS SUBCUTANEOUS INFUSION OF OCTREOTIDE (SMS-201-995) [J].
CARON, P ;
COGNE, M ;
GUSTHIOTJOUDET, B ;
WAKIM, S ;
CATUS, F ;
BAYARD, F .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 132 (03) :320-325
[6]   A PROSPECTIVE MULTICENTER OCTREOTIDE DOSE-RESPONSE STUDY IN THE TREATMENT OF ACROMEGALY [J].
EZZAT, S ;
REDELMEIER, DA ;
GNEHM, M ;
HARRIS, AG .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1995, 18 (05) :364-369
[7]   OCTREOTIDE STIMULATES INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1 - A POTENTIAL PITUITARY-INDEPENDENT MECHANISM FOR DRUG-ACTION [J].
EZZAT, S ;
REN, SG ;
BRAUNSTEIN, GD ;
MELMED, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (06) :1459-1463
[8]   OCTREOTIDE TREATMENT OF ACROMEGALY - A RANDOMIZED, MULTICENTER STUDY [J].
EZZAT, S ;
SNYDER, PJ ;
YOUNG, WF ;
BOYAJY, LD ;
NEWMAN, C ;
KLIBANSKI, A ;
MOLITCH, ME ;
BOYD, AE ;
SHEELER, L ;
COOK, DM ;
MALARKEY, WB ;
JACKSON, I ;
VANCE, ML ;
THORNER, MO ;
BARKAN, A ;
FROHMAN, LA ;
MELMED, S .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (09) :711-718
[9]   SANDOSTATIN LAR IN ACROMEGALIC PATIENTS - A DOSE-RANGE STUDY [J].
FLOGSTAD, AK ;
HALSE, J ;
HALDORSEN, T ;
LANCRANJAN, I ;
MARBACH, P ;
BRUNS, C ;
JERVELL, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (12) :3601-3607
[10]   Acromegaly: What constitutes optimal therapy? [J].
Frohman, LA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (02) :443-445